Public Market Listing
009420 KOSPI
KOSPI primary exchange listing
External market data link · No third-party exchange redistribution
Assets (2 total) 2 Total Assets
0 Approved
1 Phase 3 / Filed
1 Phase 1–2 / Early
6 Diseases
Disease: All diseases (2) Rheumatoid Arthritis (1) Myasthenia Gravis (1) Graves' Disease (1) Chronic Inflammatory Demyelinating Polyneuropathy (1) Sjögren's Disease (1) Parkinson's Disease (1)
Stage: All stages (2) Approved / Phase 4 (0) Phase 3 / Filed (1) Phase 2 Phase 1 / Preclinical
Quick filter: All (2) Rheumatoid Arthritis (1) Myasthenia Gravis (1) Graves' Disease (1) Chronic Inflammatory Demyelinating Polyneuropathy (1) Sjögren's Disease (1)
Showing 2 of 2 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Phase 3 FcRn Monoclonal antibody
Rheumatoid Arthritis Myasthenia Gravis Graves' Disease Chronic Inflammatory Demyelinating Polyneuropathy Sjögren's Disease
Phase 1 Nurr1 (NR4A2, nuclear orphan receptor) Small molecule
Upcoming events (7 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2027 (3) May 2027 (1) Imeroprubart Phase 2 Graves' Disease Est. primary completion 2027-05 ·
NCT07018323 ·
CT.gov ↗ What to watch
September 2027 (1) Imeroprubart Phase 2 Rheumatoid Arthritis Est. primary completion 2027-09 ·
NCT06754462 ·
CT.gov ↗ What to watch
December 2027 (1) Imeroprubart Phase 3 Generalized Myasthenia Gravis Est. primary completion 2027-12 ·
NCT07039916 ·
CT.gov ↗ What to watch
2028 (3) June 2028 (1) Imeroprubart Phase 2 Graves' Disease Est. primary completion 2028-06 ·
NCT06727604 ·
CT.gov ↗ What to watch
July 2028 (1) Imeroprubart Phase 2 Primary Sjögren's Syndrome Est. primary completion 2028-07 ·
NCT06979531 ·
CT.gov ↗ What to watch
August 2028 (1) Imeroprubart Phase 2 Chronic Inflammatory Demyelinating Polyneuropathy Est. primary completion 2028-08 ·
NCT07032662 ·
CT.gov ↗ What to watch
2030 (1) March 2030 (1) Imeroprubart Phase 2 Graves' Disease Est. primary completion 2030-03 ·
NCT07286006 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (2) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
November 2026 Topline result Imeroprubart Randomized withdrawal period (Period 2) in difficult-to-treat RA met its primary endpoint Recent
23 September 2026 Topline result IMVT-1402 IMVT-1402 CLE proof-of-concept study misses primary endpoint; CLE development stopped Financial reports Annual history (1 year)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $11M — — <$0.1M report ↗
Latest financial report · 2025-FY
For FY2025, the structured figures show revenue of $10.92M, a net loss of $0.04M, and a quarterly net burn of $0.04M, with R&D spend and cash position not disclosed; the company’s report separately cited record annual revenue of 155.2 billion won ($111.45M), up 12% YoY, on pharmaceutical division sales of 133.8 billion won, up 13% YoY, though operating profit slowed slightly on higher SG&A expenses.
Growth was driven by Biotop probiotic and hair-loss treatments, with Biotop reaching 23.8 billion won in annual revenue and the company guiding Biotop to 300 billion won in 2026 while planning eight product launches. In R&D, batoclimab demonstrated best-in-class efficacy in a phase 3 trial for myasthenia gravis and supportive phase 2 data in Graves’ disease, while imerofruvab (HL161ANS) entered phase 2 or registrational trials for six indications. Management expects five global clinical readouts in 2026, including phase 3 thyroid eye disease results for batoclimab, data for imerofruvab in difficult-to-treat rheumatoid arthritis and cutaneous lupus erythematosus, VELOS-4 phase 3 results for tanfanercept in dry eye disease, and progress on HL192 for Parkinson’s disease.